Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
YSBHKSE:09885 +6.77%74 Piotroski F-Score is 6 as of Aug. 23, 2026, which is at its 10-year median of 6.00. GuruFocus rates HKSE:09885 with a GF Score™ of 74/100 and a GF Value™ of HK$7.39 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 645 Healthcare Providers & Services companies, YSB ranks better than 75.19% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
YSB has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for YSB's Piotroski F-Score or its related term are showing as below:
HKSE:09885'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 7
Current: 6
During the past 6 years, the highest Piotroski F-Score of YSB was 7. The lowest was 4. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
YSB Piotroski F-Score Related Terms
YSB Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for YSB's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, YSB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YSB Piotroski F-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, YSB's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where YSB's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
YSB's current Net Income (TTM) was 169.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
YSB's current ratio of this year was 1.22366374. YSB's current ratio of last year was 1.33456023.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
YSB's number of shares in issue this year was 694.874. YSB's number of shares in issue last year was 657.347.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
YSB's gross margin of this year was 0.11001529. YSB's gross margin of last year was 0.1012897.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
YSB's asset turnover of this year was 3.34057509. YSB's asset turnover of last year was 3.35318538.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
0
+
0
+
1
+
0
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
YSB has an F-score of 6 indicating the company's financial situation is typical for a stable company.
YSB (HKSE:09885) has a Piotroski F-Score of 6 as of Aug. 23, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on YSB and its competitors. This is near median its historical median of 6.00. Over the past decade, YSB's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, YSB ranks #160 out of 645 companies in the Healthcare Providers & Services industry, placing it in the top 24.8%.
Is YSB's Piotroski F-Score too high?
YSB's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. YSB's value of 6 is 20% above this industry median. Based on the distribution chart, YSB ranks #160 out of 645 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, YSB has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does YSB's Piotroski F-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, YSB ranks #160 out of 645 companies for Piotroski F-Score. This places YSB in the top 25% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. YSB's value of 6 is 20% above this benchmark. Historically, YSB's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, YSB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 645 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. YSB's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on YSB and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. YSB's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YSB stock overvalued right now?
Based on GuruFocus' analysis, YSB (HKSE:09885) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$7.39, compared to a current price of HK$3.55 — trading 52% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Healthcare Providers & Services industry median of 5.00. YSB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For YSB (HKSE:09885), the current Piotroski F-Score is 6 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is YSB (HKSE:09885) Overvalued in 2026?
Based on GuruFocus' analysis, YSB stock appears to be undervalued.
The current stock price of HK$3.55 is trading 52% below its estimated GF Value™ of HK$7.39.
GuruFocus considers YSB to be Significantly Undervalued.
Key valuation signals for HKSE:09885:
Piotroski F-Score: 6 (near median its 10-year median of 6.00)
GF Value™: HK$7.39 vs. price of HK$3.55 (52% below fair value)
Industry Position: 20% above the Healthcare Providers & Services median (#160 of 645)
No single metric tells the full story. See the HKSE:09885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The group is engaged in the wholesale and retail of pharmaceutical and healthcare products through offline channels, retail shops, and its online platform. It also operates an online marketplace that enables pharmaceutical distributors and vendors to sell pharmaceutical and healthcare products through the Group's platform. In addition, the Group provides SaaS solutions to downstream pharmacies and primary healthcare institutions to streamline inventory and patient management, and offers system technologies and operational support services through smart healthcare systems, integrated point-of-care testing and monitoring devices, digital management systems, and smart AI doctor-aid systems.
74GF Score
Get the complete analysis for HKSE:09885
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09885 has been successfully added to your 
